AR070343A1 - Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica - Google Patents

Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica

Info

Publication number
AR070343A1
AR070343A1 ARP090100405A ARP090100405A AR070343A1 AR 070343 A1 AR070343 A1 AR 070343A1 AR P090100405 A ARP090100405 A AR P090100405A AR P090100405 A ARP090100405 A AR P090100405A AR 070343 A1 AR070343 A1 AR 070343A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
hydrogen
heteroaryl
aryl
Prior art date
Application number
ARP090100405A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR070343A1 publication Critical patent/AR070343A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0004—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements comprising amorphous/crystalline phase transition cells
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0021—Auxiliary circuits
    • G11C13/0023—Address circuits or decoders
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C13/00—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00
    • G11C13/0002—Digital stores characterised by the use of storage elements not covered by groups G11C11/00, G11C23/00, or G11C25/00 using resistive RAM [RRAM] elements
    • G11C13/0021—Auxiliary circuits
    • G11C13/003—Cell access
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/72—Array wherein the access device being a diode
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/74—Array wherein each memory cell has more than one access device
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/78—Array wherein the memory cells of a group share an access device, all the memory cells of the group having a common electrode and the access device being not part of a word line or a bit line driver
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C2213/00—Indexing scheme relating to G11C13/00 for features not covered by this group
    • G11C2213/70—Resistive array aspects
    • G11C2213/79—Array wherein the access device being a transistor
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C5/00—Details of stores covered by group G11C11/00
    • G11C5/02—Disposition of storage elements, e.g. in the form of a matrix array
    • G11C5/025—Geometric lay-out considerations of storage- and peripheral-blocks in a semiconductor storage device
    • G—PHYSICS
    • G11—INFORMATION STORAGE
    • G11C—STATIC STORES
    • G11C5/00—Details of stores covered by group G11C11/00
    • G11C5/06—Arrangements for interconnecting storage elements electrically, e.g. by wiring
    • G11C5/063—Voltage and signal distribution in integrated semi-conductor memory access lines, e.g. word-line, bit-line, cross-over resistance, propagation delay

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Estos compuestos son utiles en el tratamiento de enfermedades del sistema nervioso central tales como esquizofrenia. Reivindicacion 1: Un compuesto de formula (1) o una sal farmacéuticamente aceptable del mismo, en la que, L es >C=O, o -SO2-; Y es >C(R7) y la línea discontinua está ausente; o Y es carbono y la discontinua es un doble enlace; o Y es >N- y la línea discontinua está ausente; Z es un enlace, -(C(R2)2)-, -O-, >C=O o -S(O)t-; donde t es un numero entero seleccionado entre 0, 1 o 2; R1 se selecciona entre el grupo compuesto por hidrogeno, -CF3, alquil C1-6-, alquenil C2-6- y alquinil C2-6-; donde cada uno de los mencionados anteriormente alquil C1-6-, alquenil C2-6- y alquinil C2-6- puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; cada R2 se selecciona independientemente entre los radicales compuestos por hidrogeno, halo, -CF3, -CN, -NO2, -(C=O)R8, -(C=O)OR9, -O(C=O)R8, -OR9, -NR10R10, -SR11, -(S=O)R11, -SO2R11, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, cicloalquenil C5-10-, bicicloalquil C6-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3 hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; u opcionalmente R1 y uno de dichos R2 pueden tomarse opcionalmente junto con el carbono o nitrogeno al que están unidos para formar un anillo heterocíclico de 3 a 10 miembros opcionalmente sustituido que contiene opcionalmente uno o dos dobles o triples enlaces y que contiene opcionalmente uno o dos heteroátomos adicionales seleccionados entre N, S y O; u opcionalmente dos de dichos R2 pueden tomarse opcionalmente junto con el carbono al que están unidos para formar un anillo carbocíclico de 3 a 10 miembros opcionalmente sustituido que contiene opcionalmente uno o dos dobles o triples enlaces; y donde dicho anillo carbocíclico de 3 a 10 miembros puede contener opcionalmente 1, 2 o 3 heteroátomos seleccionados independientemente entre N, S y O; R3 se selecciona entre los radicales compuestos por hidrogeno, -CF3, -SOR11, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, cicloalquenil C5-10-, bicicloalquil C6-10-, bicicloalquenil C6-10-, heterocicloalquil C1-9-, heterocicloalquenil C2-9-, heterobicicloalquil C2-9-, heterobicicloalquenil C2-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y -heteroaril C1-9-; cada R4, R5 y R6 se selecciona independientemente entre los radicales compuestos por hidrogeno, halo, -CF3, -CN, -NO2, -(C=O)R8, -(C=O)OR9, -O(C=O)R8, -OCF3, -OR9, -NR10R10, -(NR10)(C=O)R8, -SR11, -(S=O)R11, -SO2R11, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, cicloalquenil C5-10-, bicicloalquil C6-10-, bicicloalquenil C6-10-, heterocicloalquil C1-9-, heterocicloalquenil C2-9-, heterobicicloalquil C2-9-, heterobicicloalquenil C2-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; R7 es hidrogeno, halo, -OR9 o alquil C1-6-; cada R8 se selecciona independientemente entre los radicales compuestos por hidrogeno, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre el grupo compuesto por hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, aril C6-10- y heteroaril C1-9-; cada R9 se selecciona independientemente entre los radicales compuestos por hidrogeno, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9- donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, amino, alquilamino C1-6-, di(alquil C1-6)amino-, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, aril C6-10- y heteroaril C1-9-; cada R10 se selecciona independientemente entre los radicales compuestos por hidrogeno, -SO2-alquilo C1-6, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-10-, aril C6-10- y heteroaril C1-9-; donde cada uno de los radicales mencionados anteriormente puede estar opcionalmente sustituido con uno, dos o tres sustituyentes seleccionados independientemente entre hidrogeno, halo, -CF3, -OCF3, hidroxilo, alquil C1-6-, alcoxi C1-6-, cicloalquil C3-10-, cicloalquenil C5-10, aril C6-10- y heteroaril C1-9-; cada R11 se selecciona independientemente entre el grupo compuesto por hidrogeno, amino, alquilamino C1-6-, di(alquil C1-6)amino-, -CF3, alquil C1-6-, cicloalquil C3-10-, heterocicloalquil C1-9-, aril C6-10- y heteroaril C1-9-; n es un numero entero seleccionado entre uno, dos o tres; m es un numero entero seleccionado entre cero, uno, dos, tres o cuatro; p es un numero entero seleccionado entre cero, uno, dos, tres o cuatro; y q es un numero entero seleccionado entre cero, uno, dos, tres o cuatro.
ARP090100405A 2008-02-05 2009-02-05 Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica AR070343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2619508P 2008-02-05 2008-02-05

Publications (1)

Publication Number Publication Date
AR070343A1 true AR070343A1 (es) 2010-03-31

Family

ID=40680365

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090100405A AR070343A1 (es) 2008-02-05 2009-02-05 Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica

Country Status (11)

Country Link
US (1) US20090197859A1 (es)
EP (1) EP2265600A1 (es)
JP (1) JP2011511056A (es)
AR (1) AR070343A1 (es)
CA (1) CA2714232A1 (es)
CL (1) CL2009000245A1 (es)
PA (1) PA8815001A1 (es)
PE (1) PE20091379A1 (es)
TW (1) TW200938532A (es)
UY (1) UY31632A1 (es)
WO (1) WO2009098576A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2010048012A1 (en) * 2008-10-21 2010-04-29 Merck Sharp & Dohme Corp. 2,5-disubstituted piperidine orexin receptor antagonists
TW201041869A (en) 2009-05-14 2010-12-01 Japan Tobacco Inc Azetidine compound and pharmaceutical use thereof
UA107938C2 (en) * 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
TWI558398B (zh) 2009-09-22 2016-11-21 諾華公司 菸鹼乙醯膽鹼受體α７活化劑之用途
WO2011058766A1 (en) * 2009-11-16 2011-05-19 Raqualia Pharma Inc. Aryl carboxamide derivatives as ttx-s blockers
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
WO2011147765A1 (de) 2010-05-27 2011-12-01 Bayer Cropscience Ag Pyridinylcarbonsäure derivate als fungizide
EP2632253B1 (en) * 2010-10-29 2016-04-06 Merck Sharp & Dohme Corp. Process for the preparation of an orexin receptor antagonist
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
AU2013331505A1 (en) 2012-10-16 2015-04-30 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of ROR-gamma-t
CA2888210C (en) 2012-10-16 2021-02-09 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
WO2014125233A2 (fr) * 2013-02-14 2014-08-21 Galderma Research & Development Procédé de synthèse de 4-piperidin-4-yl-benzène-1,3-diol et de ses sels et nouveau composé 4-(2,4-dihydroxy-phényl)-4-hydroxy-piperidine-1-carboxylate de tert-butyle
US20160009697A1 (en) * 2013-02-21 2016-01-14 Selvita S.A. Pyridine derivatives as 5-ht6 receptor antagonists
WO2014176142A1 (en) * 2013-04-23 2014-10-30 Merck Sharp & Dohme Corp. Hydroxy-substituted orexin receptor antagonists
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
JP6423423B2 (ja) 2013-10-15 2018-11-14 ヤンセン ファーマシューティカ エヌ．ベー． Ｒｏｒγｔのアルキル結合キノリニルモジュレーター
EP3057422B1 (en) 2013-10-15 2019-05-15 Janssen Pharmaceutica NV Quinolinyl modulators of ror(gamma)t
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
TW201811766A (zh) 2016-08-29 2018-04-01 瑞士商諾華公司 N-(吡啶-2-基)吡啶-磺醯胺衍生物及其用於疾病治療之用途
CN109721530A (zh) * 2017-10-31 2019-05-07 成都博腾药业有限公司 一种制备6-氟-2-吡啶磺酰氯的方法
WO2021019051A1 (en) 2019-07-30 2021-02-04 Karl-Franzens-Universität Graz Inhibitors of human atgl

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042524A1 (en) * 2003-10-30 2005-05-12 Virochem Pharma Inc. Pyridine carboxamide and methods for inhibiting hiv integrase

Also Published As

Publication number Publication date
US20090197859A1 (en) 2009-08-06
UY31632A1 (es) 2009-09-30
CA2714232A1 (en) 2009-08-13
WO2009098576A1 (en) 2009-08-13
EP2265600A1 (en) 2010-12-29
PE20091379A1 (es) 2009-09-18
TW200938532A (en) 2009-09-16
JP2011511056A (ja) 2011-04-07
CL2009000245A1 (es) 2009-06-05
PA8815001A1 (es) 2009-09-17

Similar Documents

Publication Publication Date Title
AR070343A1 (es) Piridinil amidas, un procedimiento para el tratamiento de la esquizofrenia en un mamifero y una composicion farmaceutica
AR119651A1 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
AR079231A1 (es) Derivados de imidazoquinolina
AR085615A1 (es) Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR099363A1 (es) Pirrolo[2,3-d]pirimidinil, pirrolo[2,3-b]pirazinil y pirrolo[2,3-d]piridinil acrilamidas
AR054481A1 (es) Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol
AR061369A1 (es) Derivados de pirimidina y composiciones farmaceuticas que los comprenden
ES2668775T3 (es) Compuestos tetracíclicos
PE20130155A1 (es) Derivados de ariletinilo
AR066492A1 (es) Derivados de imidazoquinolina, proceso para su preparacion, composiciones farmaceuticas que los contienen y usos para el tratamiento de enfermedades virales, bacterianas, alergicas y distintos tipos de canceres.
PE20140011A1 (es) Compuestos y composiciones novedosos para la inhibicion de nampt
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR045761A1 (es) Derivados de 2-piridona como inhibidores de elastasa de neutrofilos
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
ES2393824T3 (es) Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
AR075531A1 (es) Derivados de piperazin-ciclopropil benzamidas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del sistema nervioso central, tales como alzheimer y esquizofrenia, entre otros
PE20160240A1 (es) Nuevos derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR100530A1 (es) Compuestos antihelmínticos
AR068115A1 (es) Derivado del acido pirazolcarboxilico metodo de produccion del mismo y fungicida
AR061111A1 (es) Derivados de isoindol utiles para tratar dolor,trastornos gastrointestinales y cancer
PE20190980A1 (es) Compuestos terapeuticos y metodos para utilizarlos
AR109991A1 (es) Tratamientos de combinación que comprenden la administración de imidazopirazinonas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal